Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.815
-0.335 (-10.63%)
At close: Mar 18, 2026, 4:00 PM EDT
2.920
+0.105 (3.73%)
After-hours: Mar 18, 2026, 7:40 PM EDT

Galectin Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-37.3-47.05-41.07-38.78-30.53-23.47
Depreciation & Amortization
0.020.040.030.030.040.04
Stock-Based Compensation
2.052.452.262.872.081.8
Other Adjustments
8.344.953.230.480.350.09
Changes in Other Operating Activities
-3.74-2.162.584.353.750.94
Operating Cash Flow
-30.62-41.77-32.97-31.06-24.31-20.6
Long-Term Debt Issued
1630301030-
Net Long-Term Debt Issued (Repaid)
1630301030-
Issuance of Common Stock
3.481.2310.03-6.810.26
Net Common Stock Issued (Repurchased)
3.481.2310.03-6.810.26
Financing Cash Flow
15.0931.2340.031036.810.26
Net Cash Flow
-15.54-10.547.07-21.0612.51-20.34
Free Cash Flow
-30.62-41.77-32.97-31.06-24.31-20.6
Free Cash Flow Per Share
-0.49-0.67-0.55-0.52-0.42-0.36
Levered Free Cash Flow
-25.16-19.32-12.19-24.53.09-22.62
Unlevered Free Cash Flow
-32.86-44.55-35.46-33.98-26.39-22.47
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q